# BioIntellisense

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biointellisense

- Industry: Medical Devices & Equipment
- Headquarters: Golden, US
- Website: www.biointellisense.com/
- Total disclosed funding: $70M
- Latest round: Series B (Jul 28, 2021)
- Investors on record: 5

## About

BioIntellisense, Inc. is a U.S.-based company specializing in advanced remote patient monitoring solutions, utilizing innovative wearable technology to enhance patient care through continuous data collection and analytics.Founded in 2018 in Golden, US, BioIntellisense, Inc. focuses on remote patient monitoring solutions. The company was established by David Wang and James Mault. BioIntelliSense has successfully raised USD 45.00 mn in its latest funding round, a Series B on July 28, 2021, led by Chimera Capital and involving other investors such as Fresenius Medical Care Ventures and Royal Philips. To date, the company has completed three deals, with its current valuation at USD 977.40 mn.BioIntelliSense offers a comprehensive suite of remote patient monitoring (RPM) solutions, anchored by its flagship products, the BioButton® multi-patient wearable device and the BioDashboard™ system. The BioButton® is a rechargeable and reusable medical-grade device designed for continuous vital sign monitoring, enabling high-frequency data collection that supports personalized patient care and proactive clinical interventions. Its applications extend to both hospital settings and home environments, providing care for a variety of patient populations, including those with chronic conditions and those undergoing post-operative recovery. The BioIntelliSense solutions are utilized by hospitals, health systems, provider organizations, and payors in the United States and select international markets, enhancing the quality of care through data-driven insights and analytics that facilitate early detection of adverse health trends.The revenue model of BioIntelliSense primarily revolves around subscription-based services and partnerships with healthcare providers and organizations. Clients typically engage in contractual agreements for the use of the BioButton® wearables and the accompanying BioDashboard™ software, which enables comprehensive health data management and reporting. The structure of these transactions fosters ongoing relationships with healthcare systems, where revenue is generated through both initial device sales and recurring subscription fees for data analytics services. The company’s flagship products, including the BioButton® and BioDashboard™, are positioned to support scalable RPM programs, thereby maximizing revenue potential through increased adoption across healthcare settings. BioIntelliSense's service offerings are designed to address the growing demand for efficient and cost-effective care solutions, contributing positively to their financial performance.Following the Series B funding of USD 45.00 mn in July 2021, BioIntellisense, Inc. plans to utilize the capital for continued growth and global expansion of its medical-grade wearable devices and advanced data services for scalable remote care. The company is focused on launching new products and enhancing current offerings to meet the demands of new markets. Specific geographic regions targeted for expansion include international markets, although exact locations have not been specified. These initiatives are aimed at further establishing BioIntelliSense's footprint in remote patient monitoring solutions.

## Funding rounds

- Series B, Jul 28, 2021, $45M — Royal Philips, 7wireVentures, Fresenius Medical Care Ventures, Pendrell Corporation, Chimera Capital
- Series A, Dec 14, 2018, $25M — Fresenius Medical Care Ventures

## Investors

- Fresenius Medical Care Ventures (https://capitalatlas.ai/funds/fresenius-medical-care-ventures) — Series A, Series B
- Royal Philips — Series B
- 7wireVentures (https://capitalatlas.ai/funds/7wireventures) — Series B
- Pendrell Corporation — Series B
- Chimera Capital (https://capitalatlas.ai/funds/chimera-capital) — Series B